PRELOAD PRELOAD PRELOAD PRELOAD PRELOAD

Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

With five products on the market and a fully-integrated multinational organization in place, BioMarin is providing innovative therapeutics to patients with serious unmet medical needs.

LATEST NEWS

  • Medivation to Expand Global Oncology Franchise With the Acquisition of All Worldwide Rights to Talazoparib (BMN 673), a Potent PARP Inhibitor, From BioMarin...  MORE >
  • BioMarin Receives Rare Pediatric Disease Designation From FDA for Drisapersen for the Potential Treatment of Duchenne Muscular Dystrophy...  MORE >
  • Forbes Ranks BioMarin 10th Most Innovative Company in the World...  MORE >